Triumvira Immunologics
Austin
About Triumvira Immunologics
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $100.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2022)
- Website: triumvira.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Clinical Trials, Health Care
Social Profiles
Canonical: https://fsome.com/organization/triumvira-immunologics-88007 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.